154 related articles for article (PubMed ID: 34191128)
1. Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients.
Angus J; Cumpston A; Veltri L; Ross KG; Wen S; Dillaman M
Support Care Cancer; 2021 Dec; 29(12):7925-7930. PubMed ID: 34191128
[TBL] [Abstract][Full Text] [Related]
2. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD
Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the adverse effects of melphalan formulations.
Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
[TBL] [Abstract][Full Text] [Related]
5. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
Monahan K; Kleman A; Thapa B; Szabo A; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Hamadani M; Hari PN; Chhabra S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2229-2236. PubMed ID: 32920204
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
7. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
9. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.
Miller KC; Gertz MA; Buadi FK; Hayman SR; Wolf RC; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2019 Apr; 54(4):587-594. PubMed ID: 30116014
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
11. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
12. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant.
Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL
J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321
[TBL] [Abstract][Full Text] [Related]
13. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Malek E; Gupta V; Creger R; Caimi P; Vatsayan A; Covut F; Bashir Q; Champlin R; Delgado R; Rondon G; Cooper B; de Lima M; Lazarus HM; Qazilbash M
Leuk Lymphoma; 2018 Aug; 59(8):1905-1912. PubMed ID: 29295650
[TBL] [Abstract][Full Text] [Related]
14. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
Chen J; Seabrook J; Fulford A; Rajakumar I
J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
[TBL] [Abstract][Full Text] [Related]
15. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
16. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
17. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
19. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
20. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA
Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
